<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227630</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08031</org_study_id>
    <secondary_id>EORTC-08031</secondary_id>
    <secondary_id>2004-004273-28</secondary_id>
    <nct_id>NCT00227630</nct_id>
  </id_info>
  <brief_title>Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma</brief_title>
  <official_title>A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Postoperative Radiotherapy in Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium and cisplatin, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping&#xD;
      them from dividing. Pemetrexed disodium may also stop the growth of tumor cells by blocking&#xD;
      some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill&#xD;
      tumor cells. Giving combination chemotherapy before surgery may shrink the tumor so that it&#xD;
      can be removed. Giving radiation therapy after surgery may kill any tumor cells that remain&#xD;
      after surgery.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving pemetrexed disodium and cisplatin&#xD;
      followed by surgery and radiation therapy works in treating patients with malignant pleural&#xD;
      mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility of neoadjuvant chemotherapy comprising pemetrexed disodium and&#xD;
           cisplatin followed by extrapleural pneumonectomy and high-dose postoperative&#xD;
           3D-conformal radiotherapy, in terms of 90-day progression-free survival, in patients&#xD;
           with malignant pleural mesothelioma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine progression-free survival and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a non-randomized, multicenter study.&#xD;
&#xD;
        -  Neoadjuvant chemotherapy: Patients receive pemetrexed disodium IV over 10 minutes and&#xD;
           cisplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks for up to 3 courses&#xD;
           in the absence of disease progression or unacceptable toxicity. Patients are evaluated 3&#xD;
           weeks after completion of neoadjuvant chemotherapy. Patients without disease progression&#xD;
           proceed to surgery.&#xD;
&#xD;
        -  Extrapleural pneumonectomy: Within 21-56 days after completion of neoadjuvant&#xD;
           chemotherapy, patients undergo extrapleural pneumonectomy. Patients are evaluated 30&#xD;
           days after surgery. Patients without disease progression undergo high-dose 3D-conformal&#xD;
           radiotherapy.&#xD;
&#xD;
        -  High-dose 3D-conformal radiotherapy: Beginning 30-84 days after surgery, patients&#xD;
           undergo high-dose 3D-conformal radiotherapy daily for 30 days.&#xD;
&#xD;
      After completion of study treatment, patients are followed on days 42 and 90, every 3 months&#xD;
      for 1 year, and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 52 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility in terms of 90-day progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">59</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed disodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant pleural mesothelioma&#xD;
&#xD;
               -  All subtypes allowed&#xD;
&#xD;
          -  T1-3, N0-1, M0 disease&#xD;
&#xD;
               -  No N2 or N3 involvement confirmed by mediastinoscopy within 21 days before study&#xD;
                  entry&#xD;
&#xD;
          -  No clinical invasion of mediastinal structures (e.g., heart, aorta, spine, esophagus)&#xD;
&#xD;
          -  No wide-spread chest wall invasion except focal chest wall lesions&#xD;
&#xD;
          -  No clinical or radiological evidence of shrinking hemithorax&#xD;
&#xD;
          -  No clinically significant third-space fluid (e.g., pleural effusions or ascites) that&#xD;
             cannot be managed with thoracentesis or pleurodesis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Under 70&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 3,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 11 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Acceptable (predicted) post-radiotherapy renal function by semiquantitative isotope&#xD;
             renography, with a relative contribution of the contralateral kidney of ≥ 40%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Deemed to be fit enough to undergo study treatment&#xD;
&#xD;
          -  No preexisting sensory neurotoxicity &gt; grade 1&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No prior or concurrent melanoma, breast cancer, or hypernephroma&#xD;
&#xD;
          -  No other malignancy within the past 5 years except carcinoma in situ of the cervix or&#xD;
             adequately treated basal cell skin cancer&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition that would&#xD;
             preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent routine use of colony-stimulating factors during neoadjuvant&#xD;
             chemotherapy&#xD;
&#xD;
               -  Concurrent secondary prophylactic use allowed during neoadjuvant chemotherapy&#xD;
&#xD;
          -  No concurrent secondary prophylactic use of colony-stimulating factors during&#xD;
             post-operative radiotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for mesothelioma&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent hormonal cancer therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the lower neck, thorax, or upper abdomen&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent experimental medications&#xD;
&#xD;
          -  No nonsteroidal anti-inflammatory drugs or salicylates for 2 days before, during, and&#xD;
             2 days after administration of neoadjuvant chemotherapy (5 days before and 2 days&#xD;
             after for drugs with a long half-life [e.g., naproxen, piroxicam, diflunisal, or&#xD;
             nabumetone])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Van Schil, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Antwerp</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Ricerca sul Cancro</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Degli Studi di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital at Hull and East Yorkshire NHS Trust</name>
      <address>
        <city>Hull</city>
        <state>England</state>
        <zip>HU8 9HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre at Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>O'Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, Margerit S, Fink C, Stigt JA, Dingemans AM, Hasan B, Van Meerbeeck J, Baas P. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062. Eur J Cancer. 2011 Oct;47(15):2322-30. doi: 10.1016/j.ejca.2011.05.020. Epub 2011 Jun 16.</citation>
    <PMID>21684151</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, Klomp HM, Abdelrahman AM, Welch J, van Meerbeeck JP; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010 Dec;36(6):1362-9. doi: 10.1183/09031936.00039510. Epub 2010 Jun 4.</citation>
    <PMID>20525721</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epithelial mesothelioma</keyword>
  <keyword>sarcomatous mesothelioma</keyword>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>recurrent malignant mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

